Showing results (221-230 of 242) with videos related to
Sort By:
Pageof 25
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon, Jennifer A Quinn, Gamal Akabani, et al.Journal of Neuro-Oncology|December 3, 2003
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumorsJohn H Sampson, Gamal Akabani, Gary E Archer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.Scientific Reports|June 4, 2016
IGF1R as a Key Target in High Risk, Metastatic MedulloblastomaMatthew N Svalina, Ken Kikuchi, Jinu Abraham, et al.Nature Communications|May 27, 2018
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastomaBill H Diplas, Xujun He, Jacqueline A Brosnan-Cashman, et al.Nature Genetics|August 7, 2013
The integrated landscape of driver genomic alterations in glioblastomaVeronique Frattini, Vladimir Trifonov, Joseph Minhow Chan, et al.Nature Communications|January 14, 2021
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapyMatthias Gromeier, Michael C Brown, Gao Zhang, et al.Science (New York, N.Y.)|July 2, 2011
Altered telomeres in tumors with ATRX and DAXX mutationsChristopher M Heaphy, Roeland F de Wilde, Yuchen Jiao, et al.The Journal of Clinical Investigation|July 26, 2014
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesisHaizhong Feng, Giselle Y Lopez, Chung Kwon Kim, et al.Oncotarget|August 8, 2012
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomasYuchen Jiao, Patrick J Killela, Zachary J Reitman, et al.Pageof 25